Company insight
Redefining the platform device model
SHL Medical is a world-leading provider of drug delivery devices, including autoinjectors, pen injectors and wearable drug delivery systems. With more platform products emerging in the autoinjector space, SHL sought to redefine how platform device technologies can disrupt the market.
T
he injectable drug delivery industry as a whole has been moving towards developing platform technologies. The current notion of platform devices is, however, still relatively premature compared with other areas of the industry. That is having a preset design with cohesive architecture that can be shared by all of the products in the same family to support faster development time and reduce costs.
But the conventional scope is now posing new challenges to device developers, especially when a distinct industrial design or specific primary container type becomes a necessary element to accommodate new generations of medications and different patients’ needs. What these device companies need ultimately are designs and production processes that can offer flexibility beyond the traditional platform technology – a modular platform technology.
Modularity built on a platform The concept of modularity originates from the general attempt to operationalise and understand many complex systems. In a modular platform, the product is divided into modules that can be swapped with other elements of different sizes or functionality to create variants. Asset flexibility, cost of goods and investment deferment are some of the key drivers behind modular systems. When done correctly, modularity supports standardisation, repeatability and customisation.
Modularity in the autoinjector industry therefore refers to having a solution that leverages the benefits of a platform device technology while still allowing
components, Molly enables design feature modifications to differentiate a device’s appearance − such as the colour of the cap and needle covers − for branding and market differentiation as well as for patient distinguishability and usability. Molly’s modularity further extends to various layers of the device development process, including component assembly and final device testing.
The mature infrastructure of SHL’s in-house design and development ecosystem makes it possible to share manufacturing assets across multiple Molly device projects, resulting in the simplification of the development process and the optimisation of project timelines.
Flexibility is key
The Molly autoinjector is built on a modular platform technology designed to support shorter development timelines.
various customisations in the device design and development models. Such a concept is reflected in the latest generation of SHL Medical’s Molly, a modular platform that enables bespoke customisations in the front and rear sub- assemblies of discrete device projects. As a modular platform, Molly’s device designs can be configured according to pharma and customers’ needs. Both the 1.0ml and 2.25ml Molly autoinjectors are equipped with a modular design that enables a certain level of flexibility for customisation in its industrial design while maintaining its rotator-based mechanism. With front and rear modules comprising its core
World Pharmaceutical Frontiers /
www.worldpharmaceuticals.net
The autoinjector market will become increasingly patient-focused, creating an imperative for flexible and modular tools and technologies. As one of the world’s first high- volume (≥2.0ml) autoinjectors to be commercialised, the flexibility offered by Molly’s modular platform technology has been successfully utilised in multiple commercial launches for various disease areas. The success further validates the stratification of the device offerings in the market and puts the technology in a unique position.
The true value of Molly, however, lies in its flexible design and development model, which allows for future extension – including production scalability and life-cycle management − in response to industrial advancements in fields such as data science, connectivity and sustainability. ●
www.shl-medical.com 19
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65
